Approval · Notice of Compliance 23055 · 2019
PRO-GABAPENTIN: Notice of Compliance 23055
Issued December 30, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23055
- Date
- December 30, 2019
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Companies
- Canadian reference product
- NEURONTIN (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRO-GABAPENTIN | 02310473 | Marketed |
| PRO-GABAPENTIN | 02310481 | Marketed |
Medicinal ingredients
- GABAPENTIN 600 MG per TAB
- GABAPENTIN 800 MG per TAB